Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · Real-Time Price · USD
2.330
+0.040 (1.75%)
At close: Mar 13, 2026, 4:00 PM EDT
2.410
+0.080 (3.43%)
After-hours: Mar 13, 2026, 6:47 PM EDT

Company Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.

The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.

It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.

In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs.

It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J.

Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology, Inc.
Nautilus Biotechnology logo
CountryUnited States
Founded2016
IndustryBiotechnology
SectorHealthcare
Employees130
CEOSujal Patel

Contact Details

Address:
2701 Eastlake Avenue East
Seattle, Washington 98102
United States
Phone206 333 2001
Websitenautilus.bio

Stock Details

Ticker SymbolNAUT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1808805
CUSIP Number63909J108
ISIN NumberUS63909J1088
Employer ID98-1541723
SIC Code3826

Key Executives

NamePosition
Sujal M. PatelCo-Founder, Chief Executive Officer, President, Secretary and Director
Dr. Parag Mallick Ph.D.Co-Founder, Chief Scientist and Director
Kentaro SuzukiChief Marketing Officer
Anna MowryChief Financial Officer and Treasurer
Matthew B. Murphy ESQ.General Counsel
Gwen E. WeldChief People Officer
Dr. Subra Sankar Ph.D.Senior Vice President of Product Development

Latest SEC Filings

DateTypeTitle
Mar 4, 2026SCHEDULE 13D/AFiling
Mar 4, 2026SCHEDULE 13D/AFiling
Feb 26, 2026S-8Securities to be offered to employees in employee benefit plans
Feb 26, 202610-KAnnual Report
Feb 26, 20268-KCurrent Report
Nov 4, 20258-KCurrent Report
Oct 28, 202510-QQuarterly Report
Oct 28, 20258-KCurrent Report
Jul 31, 202510-QQuarterly Report
Jul 31, 20258-KCurrent Report